Politiparty
Politiparty

119th Congress Health

H.R. 1672: Maintaining Investments in New Innovation Act

Introduced

  1. Introduced (completed)Feb 27, 2025
  2. Passed House (not reached)
  3. Passed Senate (not reached)
  4. To the President (not reached)
  5. Became law (not reached)

Summary

Introduced in House, Feb 27, 2025

This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)

Written by the Congressional Research Service, Library of Congress.

Roll calls

0 votes on this bill

No roll call votes have been held on this bill.

Amendments

0 offered

No amendments were offered to this bill.

Cosponsors

51

Bipartisan support.

Who scored on this bill

18 points earned
  1. 1Donald Davis D-NC SponsorDrew cross-party cosponsors, introduced, reached a cosponsor milestone4 events+18
See all scorers and every scoring event

Introductions and cosponsorships count toward weekly caps and show no points.

Other bills by Donald Davis

History

  1. Feb 27, 2025Introduced in the House by Donald Davis.
Show the full action history (2 actions)
  1. Feb 27, 2025Introduced in House
  2. Feb 27, 2025Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.